Short leukocyte telomere length predicts poor prognosis and indicates altered immune functions in colorectal cancer patients

Annals of Oncology

Volumn 25, Issue 4, 2014, Pages 869-876

  Chen, Y ^a   Qu, F ^a   He, X ^b   Bao, G ^b   Liu, X ^c   Wan, S ^d   Xing, J ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^d HENAN UNIVERSITY   (China)

Author keywords

Colorectal cancer; Cytokine; Immunophenotype; Leukocyte relative telomere length; Overall survival; Relapse free survival

Indexed keywords

CAPECITABINE; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; ARTICLE; B LYMPHOCYTE; CANCER PROGNOSIS; CANCER STAGING; CD4+ T LYMPHOCYTE; COLORECTAL CANCER; COLORECTAL SURGERY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; LEUKOCYTE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OVERALL SURVIVAL; PERIPHERAL BLOOD MONONUCLEAR CELL; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECURRENCE FREE SURVIVAL; TELOMERE HOMEOSTASIS; TREATMENT OUTCOME; TUMOR IMMUNITY; AGED; COLORECTAL NEOPLASMS; DISEASE FREE SURVIVAL; GENETICS; IMMUNOLOGY; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PROGNOSIS; RISK FACTOR; TELOMERE; TELOMERE SHORTENING;

AGED; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOPHENOTYPING; LEUKOCYTES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RISK FACTORS; TELOMERE; TELOMERE SHORTENING;

EID: 84897104144     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu016     Document Type: Article

References (24)

1. Jemal A, Bray F, Center MM et al. Global cancer statistics. CA Cancer J Clin 2011; 61:69-90.
2. Shia J, Klimstra DS, Bagci P et al. TNM staging of colorectal carcinoma: issues and caveats. Semin Diagn Pathol 2012;29:142-153.
3. Xu L, Li S, Stohr BA. The role of telomere biology in cancer. Annu Rev Pathol 2013;8:49-78.
4. Bekaert S, De Meyer T, Van Oostveldt P. Telomere attrition as ageing biomarker. Anticancer Res 2005;25:3011-3021.
5. Rampazzo E, Bertorelle R, Serra L et al. Relationship between telomere shortening, genetic instability, and site of tumour origin in colorectal cancers. Br J Cancer 2010;102:1300-1305.
6. Svenson U, Roos G. Telomere length as a biological marker in malignancy. Biochim Biophys Acta 2009;1792:317-323.
7. Hou L, Zhang X, Gawron AJ et al. Surrogate tissue telomere length and cancer risk: shorter or longer? Cancer Lett 2012;319:130-135.
8. Svenson U, Nordfjall K, Stegmayr B et al. Breast cancer survival is associated with telomere length in peripheral blood cells. Cancer Res 2008;68: 3618-3623.
9. Svenson U, Ljungberg B, Roos G. Telomere length in peripheral blood predicts survival in clear cell renal cell carcinoma. Cancer Res 2009;69:2896-2901.
10. Liu HQ, An JZ, Liu J et al. Leukocyte telomere length predicts overall survival in hepatocellular carcinoma treated with transarterial chemoembolization. Carcinogenesis 2012;33:1040-1045.
11. Zlobec I, Vuong T, Hayashi S et al. A simple and reproducible scoring system for EGFR in colorectal cancer: application to prognosis and prediction of response to preoperative brachytherapy. Br J Cancer 2007;96:793-800.
12. Kong CM, Lee XW, Wang X. Telomere shortening in human diseases. FEBS J 2013;280:3180-3193.
13. Wentzensen IM, Mirabello L, Pfeiffer RM et al. The association of telomere length and cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2011;20: 1238-1250.
14. Meeker AK, Hicks JL, Iacobuzio-Donahue CA et al. Telomere length abnormalities occur early in the initiation of epithelial carcinogenesis. Clin Cancer Res 2004;10: 3317-3326.
15. Kaszubowska L. Telomere shortening and ageing of the immune system. J Physiol Pharmacol 2008;59 (Suppl 9):169-186.
16. Iancu EM, Speiser DE, Rufer N. Assessing ageing of individual T lymphocytes: mission impossible? Mech Ageing Dev 2008;129:67-78.
17. Damjanovic AK, Yang Y, Glaser R et al. Accelerated telomere erosion is associated with a declining immune function of caregivers of Alzheimer's disease patients. J Immunol 2007;179:4249-4254.
18. Namm JP, Li Q, Lao X et al. B lymphocytes as effector cells in the immunotherapy of cancer. J Surg Oncol 2012;105:431-435.
19. Sung JL, Lin JT, Gorham JD. CD28 co-stimulation regulates the effect of transforming growth factor-beta1 on the proliferation of naive CD4+ T cells. Int Immunopharmacol 2003;3:233-245.
20. Snapper CM, Waegell W, Beernink H et al. Transforming growth factor-beta 1 is required for secretion of IgG of all subclasses by LPS-activated murine B cells in vitro. J Immunol 1993;151:4625-4636.
21. Malaguarnera M, Cristaldi E, Romano G et al. Autoimmunity in the elderly: implications for cancer. J Cancer Res Ther 2012;8:520-527.
22. Svenson U, Gronlund E, Soderstrom I et al. Telomere length in relation to immunological parameters in patients with renal cell carcinoma. PLoS One 2013; 8: e55543.
23. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Ann Rev Immunol 2007;25:267-296.
24. Roth AD, Delorenzi M, Tejpar S et al. Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer. J Natl Cancer Inst 2012;104: 1635-1646.